Home » Stocks » CRDF

Cardiff Oncology, Inc. (CRDF)

Stock Price: $8.28 USD -0.50 (-5.69%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $8.27 -0.01 (-0.12%) Apr 16, 7:44 PM
Market Cap 306.79M
Revenue (ttm) 365,993
Net Income (ttm) -22.60M
Shares Out 20.87M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $8.28
Previous Close $8.78
Change ($) -0.50
Change (%) -5.69%
Day's Open 8.84
Day's Range 8.27 - 8.94
Day's Volume 534,938
52-Week Range 0.83 - 25.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: ADBE, KNSL, NBRV, VEEV
3 days ago - Zacks Investment Research

Cardiff Oncology Inc (NASDAQ: CRDF) has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in second-line KRAS-mutated metastatic colorectal c...

5 days ago - Benzinga

SAN DIEGO, April 12, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new tre...

5 days ago - PRNewsWire

SAN DIEGO, April 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new tre...

1 week ago - PRNewsWire

SAN DIEGO, April 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new tre...

1 week ago - PRNewsWire

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new trea...

1 week ago - PRNewsWire

These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first o...

Other stocks mentioned: ATRA, BLI, CGEN, CIDM, KERN, ZDGE
1 week ago - InvestorPlace

Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...

3 weeks ago - Zacks Investment Research

SAN DIEGO, March 11, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment...

1 month ago - PRNewsWire

SAN DIEGO, March 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment...

1 month ago - PRNewsWire

SAN DIEGO, March 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment ...

1 month ago - PRNewsWire

Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Cardiff Oncology Inc (NASDAQ: CRDF) has announced updated data from its Phase 2 trial evaluating the oral combination of onvansertib, Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone), and prednisone...

2 months ago - Benzinga

Some medical stocks gained momentum because of the pandemic, while others focus on high-reward challenges like cancer treatment. The post 7 Healthy Medical Stocks to Buy appeared first on InvestorPlace.

Other stocks mentioned: AMED, FLGT, GHSI, NTRA, OMI, TDOC
2 months ago - InvestorPlace

This cancer specialist is looking to defeat the KRAS mutation.

2 months ago - The Motley Fool

Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

The biotech presented data from an early-stage study of its experimental colorectal cancer drug.

3 months ago - The Motley Fool

SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing new treatment options for cancer patients in indications with the greate...

3 months ago - PRNewsWire

Biotech, bitcoin, and renewable energy led the way.

Other stocks mentioned: BEEM, BLNK, BTBT, MARA, NIO, NVAX, RIOT ...
3 months ago - The Motley Fool

These clinical-stage drug developers were unstoppable last year.

Other stocks mentioned: NVAX, VXRT
3 months ago - The Motley Fool

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opport...

Other stocks mentioned: GNPX, NVAX, TRIL, VXRT
3 months ago - Benzinga

These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.

Other stocks mentioned: CLDX, CODX, RVP, VXRT
3 months ago - The Motley Fool

SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment ...

3 months ago - PRNewsWire

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

Other stocks mentioned: BNTX, CLDX, CODX, MCRB, MRNA, NSRGY, NVAX ...
4 months ago - The Motley Fool

Biotech investors had more than just vaccines to think about this year.

Other stocks mentioned: FPRX, MRSN, SURF, TRIL
4 months ago - The Motley Fool

SAN DIEGO, Dec. 6, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment o...

4 months ago - PRNewsWire

Here's why shares of these drugmakers seem unstoppable this year.

Other stocks mentioned: CLDX
6 months ago - The Motley Fool

An analyst's bullish outlook sent the biotech stock soaring.

6 months ago - The Motley Fool

SAN DIEGO, Sept. 29, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new t...

6 months ago - PRNewsWire

Any time there is good news that drives a stock higher, some investors know that the companies making the news may use the strength to raise additional capital. Not all secondary offerings come on the h...

Other stocks mentioned: ARQT, FCEL, IMXI, LAD, OMI
6 months ago - 24/7 Wall Street

SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Cardiff Oncology, Inc.

7 months ago - PRNewsWire

SAN DIEGO, Aug. 11, 2020 /PRNewswire/ -- Cardiff Oncology, Inc.

8 months ago - PRNewsWire

Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second quarter. ...

Other stocks mentioned: CNCE, IDN, REPH, VRTV
9 months ago - Forbes

As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you today.

Other stocks mentioned: BCRX, ECOR, PDSB, TTPH
9 months ago - Forbes

About CRDF

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zyti... [Read more...]

Industry
Biotechnology
Founded
1999
CEO
Mark Erlander
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
CRDF
Full Company Profile

Financial Performance

In 2020, CRDF's revenue was $365,993, an increase of 49.61% compared to the previous year's $244,632. Losses were -$19.31 million, 17.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is 26.25, which is an increase of 217.03% from the latest price.

Price Target
$26.25
(217.03% upside)
Analyst Consensus: Buy